SCHEMBL1005149

SCHEMBL1005149

CCc1c2c(nc3ccccc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP1 P11387 18/20 0.85
MEN1 O00255 3/20 0.81
KMT2A Q03164 3/20 0.81
ALDH1A1 P00352 3/20 0.70
GLA P06280 3/20 0.70
KDM4E B2RXH2 2/20 0.70
TP53 P04637 2/20 0.70
HPGD P15428 2/20 0.70
SMN1; SMN2 Q16637 2/20 0.70
STAT6 P42226 1/20 0.70
CHEK1 O14757 1/20 0.70
HDAC3 O15379 1/20 0.70
ABCC4 O15439 1/20 0.70
GMNN O75496 1/20 0.70
LMNA P02545 1/20 0.70
CYP1A2 P05177 1/20 0.70
CYP3A4 P08684 1/20 0.70
HNRNPA1 P09651 1/20 0.70
GAA P10253 1/20 0.70
ALOX15 P16050 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29363060 1.00 TOP1 (0.85) TOP1MEN1KMT2AALDH1A1GLA
SCHEMBL29649464 1.00 TOP1 (0.85) TOP1MEN1KMT2AALDH1A1GLA
SCHEMBL19236135 1.00 TOP1 (0.85) TOP1MEN1KMT2AALDH1A1GLA
Hydrochloric Acid SCHEMBL27410778 0.99 TOP1 (0.84) TOP1MEN1KMT2AALDH1A1GLA
Ammonia Solution, Strong SCHEMBL28299902 0.99 TOP1 (0.84) TOP1MEN1KMT2AALDH1A1GLA
SCHEMBL27426962 0.99 TOP1 (0.84) TOP1MEN1KMT2AALDH1A1GLA
Boric Acid SCHEMBL28731501 0.98 TOP1 (0.83) TOP1MEN1KMT2AALDH1A1GLA
SCHEMBL31294345 0.95 TOP1 (0.80) TOP1MEN1KMT2AALDH1A1GLA
SCHEMBL10130707 0.94 TOP1 (0.84) TOP1MEN1KMT2AALDH1A1GLA
SCHEMBL400254 0.94 TOP1 (0.84) TOP1MEN1KMT2AALDH1A1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 937 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119950749-A Polymer-based macromolecular prodrugs 费城儿童医院 2025-05-09 CN claimed
WO-2025077823-A1 DRUG CONJUGATE FOR INTEGRIN RECEPTOR AND USE THEREOF 海思科医药集团股份有限公司 2025-04-17 WO claimed
CN-116082546-B Aminopeptidase catalyzed hydrolysis induced charge turnover polymer and application thereof 浙江大学 2025-03-11 CN claimed
EP-3595697-B1 CLEAVABLE ESTERS FOR NANOCARRIER-BASED CANCER THERAPY CHILDRENS HOSPITAL PHILADELPHIA (US) 2025-02-12 EP claimed
US-20240423973-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS LERCHEN, HANS-GEORG (DE) 2024-12-26 US claimed
US-20240390868-A1 PRODUCTION SYSTEM AND METHOD FOR PRODUCING NANOPARTICLES SHANGHAI BEST-LINK BIOSCIENCE, LLC (CN) 2024-11-28 US claimed
CN-118662648-A GRPR targeting conjugates 西藏海思科制药有限公司 2024-09-20 CN claimed
CN-118556062-A Compounds, pharmaceutical compositions and methods for treating, preventing or managing hyperproliferative disorders 文赛克斯制药有限责任公司 2024-08-27 CN claimed
CN-118511888-A Sugarcane field weeding composition containing 7-ethylcamptothecin and saflufenacil and application thereof 广西壮族自治区农业科学院 2024-08-20 CN claimed
CN-118511892-A Rice field weeding composition containing 7-ethylcamptothecin and bensulfuron methyl and application thereof 广西壮族自治区农业科学院 2024-08-20 CN claimed
WO-2002000168-A2 COMBINATION HIV THERAPY INCLUDING CAMPTOTHECIN SUPERGEN, INC. (US) 2002-01-03 WO claimed
CN-1323199-A Liposome-Encapsulated Topoisomerase Inhibitors ALZA CORP (US) 2001-11-21 CN claimed
EP-1121102-A1 LIPOSOME-ENTRAPPED TOPOISOMERASE INHIBITORS Alza Corporation (US) 2001-08-08 EP claimed
WO-2000023052-A1 LIPOSOME-ENTRAPPED TOPOISOMERASE INHIBITORS ALZA CORPORATION (US) 2000-04-27 WO claimed
EP-0758237-A1 LACTONE STABLE FORMULATION OF CAMPTOTHECIN OR 7-ETHYL CAMPTOTHECIN BIONUMERIK PHARMACEUTICALS, INC. (US) 1997-02-19 EP claimed
US-5604233-A WATER SOLUBLE ANTITUMOR, ANTICANCER AGENT BIONUMERIK PHARMACEUTICALS, INC. (US) 1997-02-18 US claimed
WO-1995029677-A1 LACTONE STABLE FORMULATION OF CAMPTOTHECIN OR 7-ETHYL CAMPTOTHECIN BIONUMERIK PHARMACEUTICALS, INC. (US) 1995-11-09 WO claimed
EP-0296612-B1 Camptothecin derivatives and process for preparing same YAKULT HONSHA KK (JP) 1994-06-22 EP claimed
EP-0296612-A1 Camptothecin derivatives and process for preparing same KABUSHIKI KAISHA YAKULT HONSHA (JP) 1988-12-28 EP claimed
EP-0137145-B1 NEW CAMPTOTHECIN DERIVATIVES AND PROCESS FOR PREPARING SAME KABUSHIKI KAISHA YAKULT HONSHA (JP) 1988-04-27 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240390868-A1 PRODUCTION SYSTEM AND METHOD FOR PRODUCING NANOPARTICLES TNF, DHPS, PPOX TOP1 702/4885MEN1 1602/4885KMT2A 4304/4885
US-20240423973-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS PCNA, TP53, BRCA1 TOP1 66/4885MEN1 1101/4885KMT2A 3750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.